Terms: = Lymphoma AND FOXL2, BPES, 668, ENSG00000183770, P58012, PFRK, POF3, PINTO, BPES1 AND Diagnosis
17 results:
1. Disparities in Time to diagnosis Among Patients With Multiple Myeloma.
Lin OM; Paine D; Gramling E; Menon M
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e379-e385. PubMed ID: 37612207
[TBL] [Abstract] [Full Text] [Related]
2. Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study.
Ashruf OS; Orozco Z; Kaelber DC
Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):626-632. PubMed ID: 37208255
[TBL] [Abstract] [Full Text] [Related]
3. Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective.
Moertl B; Dreyling M; Schmidt C; Hoster E; Schoel W; Bergwelt-Baildon MV; Berger K
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):474-482. PubMed ID: 35033478
[TBL] [Abstract] [Full Text] [Related]
4. A medicare database analysis of practice patterns in patients with mantle cell lymphoma.
Weaver JA; Peng Y; Ji Y; Gilbertson D; Pease DF; Morrison VA
J Geriatr Oncol; 2021 Jul; 12(6):894-901. PubMed ID: 33423932
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of
Lu RQ; Wu LX; Zhang J; Qin YZ; Liu YR; Lai YY; Jiang H; Chang YJ; Ruan GR; Huang XJ
Hematology; 2021 Dec; 26(1):9-15. PubMed ID: 33357137
[TBL] [Abstract] [Full Text] [Related]
6. [Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL].
Huang P; Chen S; Yang X; Lei YY; Xu XY; Liu YX; Guo YH; Pan Y; Wang XH; Zhang HL; Fu K; Meng B
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):589-593. PubMed ID: 32397023
[No Abstract] [Full Text] [Related]
7. CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.
Hu Z; Sun Y; Schlette EJ; Tang G; Li S; Xu J; Yin CC; Young KH; Patel KP; Miranda RN; Goswami M; Wang M; Jorgensen JL; Medeiros LJ; Wang SA
Mod Pathol; 2018 Feb; 31(2):327-336. PubMed ID: 28984300
[TBL] [Abstract] [Full Text] [Related]
8. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at diagnosis for Patients with Diffuse Large B-Cell lymphoma.
Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S
Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916
[TBL] [Abstract] [Full Text] [Related]
9. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
Yağcı M; Karakaya F; Suyanı E; Haznedar R
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic significance of serum proangiogenic molecules in patients with de novo non-Hodgkin lymphomas.
Rujirojindakul P; Lekhakula A
ScientificWorldJournal; 2012; 2012():215231. PubMed ID: 22629121
[TBL] [Abstract] [Full Text] [Related]
11. A population-based assessment of mortality and morbidity patterns among patients with thymoma.
Gadalla SM; Rajan A; Pfeiffer R; Kristinsson SY; Björkholm M; Landgren O; Giaccone G
Int J Cancer; 2011 Jun; 128(11):2688-94. PubMed ID: 20669226
[TBL] [Abstract] [Full Text] [Related]
12. Survival outcome in childhood ALL: experience from a tertiary care centre in North India.
Kulkarni KP; Marwaha RK; Trehan A; Bansal D
Pediatr Blood Cancer; 2009 Aug; 53(2):168-73. PubMed ID: 19405133
[TBL] [Abstract] [Full Text] [Related]
13. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Mounier N; Brice P; Divine M; Morschhauser F; Gabarre J; Blay JY; Voillat L; Lederlin P; Stamatoullas A; Bienvenu J; Guiguet M; Intrator L; Grandjean M; Brière J; Ferme C; Salles G;
J Clin Oncol; 2007 May; 25(13):1732-40. PubMed ID: 17389336
[TBL] [Abstract] [Full Text] [Related]
14. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
[TBL] [Abstract] [Full Text] [Related]
15. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance.
Gobbi PG; Ghirardelli ML; Solcia M; Di Giulio G; Merli F; Tavecchia L; Bertè R; Davini O; Levis A; Broglia C; Maffè GC; Ilariucci F; Dore R; Ascari E
J Clin Oncol; 2001 Mar; 19(5):1388-94. PubMed ID: 11230483
[TBL] [Abstract] [Full Text] [Related]
16. Circulating levels of soluble CD23 reflect clinical and biological features of leukemic B-cell chronic lymphoproliferative disorders.
Vinante F; Vassanelli A; Zanotti R; Nadali G; Krampera M; Vincenzi C; Morosato L; Chilosi M; Pizzolo G
Int J Clin Lab Res; 1995; 25(4):189-94. PubMed ID: 8788546
[TBL] [Abstract] [Full Text] [Related]
17. Use of the working formulation for non-Hodgkin's lymphoma in epidemiologic studies: agreement between reported diagnoses and a panel of experienced pathologists.
Dick F; VanLier S; Banks P; Frizzera G; Witrak G; Gibson R; Everett G; Schuman L; Isacson P; O'Conor G
J Natl Cancer Inst; 1987 Jun; 78(6):1137-44. PubMed ID: 3473254
[TBL] [Abstract] [Full Text] [Related]
